Diabetic Foot Osteomyelitis, Osteomyelitis
Conditions
Keywords
Diabetes, Osteomyelitis, Foot Infection, Phage Treatment, Bacteriophage, Phage, Bone Infection
Brief summary
This is a phase 2b randomized trial designed to evaluate bacteriophage therapy in subjects with diabetic foot osteomyelitis.
Detailed description
This study will evaluate the safety and efficacy of bacteriophage therapy in subjects with diabetic foot osteomyelitis (DFO). Enrolled subjects will have osteomyelitis infections due to Staph aureus. This study will include eligible subjects who have undergone or are planning to undergo surgical debridement of DFO.
Interventions
BIOLOGICALBacteriophage Therapy
Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
OTHERPlacebo
Placebo (normal saline)
Sponsors
Adaptive Phage Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Double-blind: Patient will be randomized to receive either active phage or placebo treatment.
Intervention model description
2:1, phage: placebo
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male or female ≥18 to \<85 years of age. * Ongoing diagnosis of diabetes. * Have undergone or are scheduled to undergo surgical debridement for DFO as part of SoC, with the associated bone culture positive for S. aureus * Availability of at least 1 matching phage for S. aureus cultured from the bone culture * Receiving SoC treatment for DFO, including antibiotics after debridement and before randomization * Meet defined study ulcer requirements as defined in the protocol * Adequate circulation to the affected extremity demonstrated within 3 months prior to randomization and no revascularization procedure anticipated * History of compliance with prior appointments and treatments in the investigator's opinion and willingness to receive and comply with SOC antimicrobial and clinical treatments for the study ulcer, including offloading
Exclusion criteria
* Healing of the ulcer by more than 30% between screening and randomization. * Treated with hyperbaric oxygen or cellular/tissue products with 30 days of screening * Suspicion of neoplasm associated with the study ulcer or any non-study diabetic ulcer independent of biopsy result. * Presence of any cellulitis not localized to the study ulcer. * Indwelling hardware at the site of the DFO. * Body weight \<50 kg. * Presence of above ankle ulcer, with \>50% above medial malleolus * Hemoglobin \< 7g/dL * Abnormal liver function tests * History of underlying liver disease at screening or within last 3 months * Positive test for HIV-1 and /or HIV-2 * Any other clinically significant or severe disease that in the judgment of the investigator makes the patient unfit for the study or likely to withdraw prematurely from the study, or that could jeopardize the safety of the patient or confound the results of the study. * Known allergy to phage products. * Pregnant and/or breastfeeding. * Immunocompromised at screening in the judgment of the investigator. * Taking any systemic or topical antibacterial antibiotic within 2 weeks prior to the start of study treatment, for a condition other than Diabetic Foot Infection and DFO. * Taking any antiviral medication within 2 weeks prior to the start of study treatment and up through the last administration of study treatment. * Taking and/or receiving any therapies for the study ulcer that are not considered to be SOC. * More than 30 days has elapsed between screening and randomization (start of treatment) * Participating in another clinical trial within 4 weeks prior to screening. * Inability to obtain or provide informed consent or adhere to the protocol in the judgment of the investigator. * Once approximately 30% of subjects are enrolled with DFO involving digits, additional subjects will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent area reduction of study ulcer through Week 13 | Baseline through Week 13 | Percent area reduction of the study ulcer surface area from baseline through Week 13 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete healing of the study ulcer | Baseline through Week 13 | Time to complete healing of the ulcer at any time point during the study |
| Time to 85% reduction of C-reactive protein (CRP) | Baseline through Week 13 | Time to 85% reduction of CRP at any time point during the study |
| Microbiological eradication of the target pathogen | baseline through Week 13 | Percentage of patients with microbiological eradication of the target pathogen at each time point during the study. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Treatment-emergent AEs due to phage therapy | baseline through Week 12 | Number and percent of treatment-emergent Adverse Events |
Countries
United States
Outcome results
None listed